A randomized, double-blinded, placebo-controlled trial in 692 subjects with mild-moderate Alzheimer’s disease to evaluate the efficacy and safety of NO-AD, a tree-derived carbohydrate that targets beta-amyloid, neuroinflammation, and other manifestations of the disease. Subjects received either 250 mg of the study drug or a placebo twice per day. The primary outcome measure was improvement on the ADAS-cog after 36 weeks.: To which of the clinical stages the above description belong?: 1. Pre-clinical research 2. Phase 1 clinical trial 3. Phase 2 clinical trial 4. Phase 3 clinical trial